FOLFIRI is achemotherapy regimen for treatment ofcolorectal cancer. It is made up of the following drugs:^[1]

• FOL –folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context decreases the cytotoxicity of 5-fluorouracil;
• F –fluorouracil (5-FU), apyrimidine analog andantimetabolite which incorporates into the DNA molecule and stops synthesis; and
• IRI –irinotecan (Camptosar), atopoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.

FOLFIRI is used forcolorectal cancer andgastric cancer.^[2] FOLFIRI is effective in the treatment of metastatic colorectal cancer, but it has not been shown to be effective in theadjuvant therapy of colon and rectal cancer.

The regimen consists of:

• irinotecan (180 mg/m² IV over 90 minutes) concurrently with folinic acid (400 mg/m² [or 2 x 250 mg/m²] IV over 120 minutes)
• followed by fluorouracil (400–500 mg/m² IV bolus) then fluorouracil (2400–3000 mg/m² intravenous infusion over 46 hours).

This cycle is typically repeated every two weeks. The dosages shown above may vary from cycle to cycle.

FOLFIRI is often^{[citation needed]} combined withbevacizumab,aflibercept,cetuximab orpanitumumab to improve efficacy and response rate.^[3]

In the short term, irinotecan causes diarrhea, which may be acute or delayed in onset. Long term use^{[citation needed]} of irinotecan may lead toneutropenia.^[4]

• Dose-dense chemotherapy
• FOLFIRINOX
• FOLFOX
• FOLFOXIRI
• IFL

• Chemotherapy regimens used in colorectal cancer

• Articles with short description
• Short description is different from Wikidata
• All articles with unsourced statements
• Articles with unsourced statements from January 2017